Notice for isatuximab (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
isatuximab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrated injection
Indication
The treatment of plasma cell myeloma.
Therapeutic area
Haematology